The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55

@article{Schuelert2011TheAC,
  title={The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55},
  author={Niklas Schuelert and Jason J. McDougall},
  journal={Neuroscience Letters},
  year={2011},
  volume={500},
  pages={72-76}
}

Figures from this paper

O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment
TLDR
O-1602 therapy improved signs of depression and detrusor contractility in animals exposed to the corticosterone treatment and reduced the oxidative damage in the urinary bladder and neuroinflammation, allowing to suggest that in the future the modulation of atypical cannabinoid receptors GPR55 could have a potential role in the treatment of Depression and overactive bladder.
Cannabinoid receptors and pain
TLDR
The role of cannabinoids and ECs in the brain stem–spinal pathway of pain inhibition is examined and pharmacological tools modulating the interaction of cannabinoids with its receptors and the treatment of pain by the augmentation of EC levels, specifically anandamide, are discussed.
Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice
TLDR
It is suggested that activation of GPR55 leads to inhibition of neurogenic contractions in the gut and are predominantly prejunctional.
Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice
TLDR
In conclusion, genetic deletion of GPR55 did not alter the development of pathological pain in adult mice in any chronic pain model evaluated.
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55
TLDR
Novel data is summarized supporting that, besides cannabinoid CB1 and CB2 receptors, GPR18 and GPR55 may be useful for pain treatment and evidence to support an antinociceptive role is summarized.
Stimulation of atypical cannabinoid receptor GPR55 abolishes the symptoms of detrusor overactivity in spontaneously hypertensive rats.
The role of the cannabinoid system in opioid analgesia and tolerance.
  • E. Ozdemir
  • Biology, Medicine
    Mini reviews in medicinal chemistry
  • 2020
TLDR
The data indicating that with combining cannabinoids and opioids drugs may be able to produce long-term analgesic effects, while preventing the opioid analgesic tolerance are summarized.
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands
  • Mellar P. Davis
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 2014
TLDR
Most clinically productive development of cannabinoids over the next 5 years will be in the area of selective CB2r agonists, which will be tested in various inflammatory, osteoarthritis and neuropathic pains.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints
TLDR
The results show that anandamide, at high doses, can activate nociceptive afferents innervating the rat knee joints, in contrast with its widely described analgesic actions.
Participation of NK1 receptors in nociceptin-induced modulation of rat knee joint mechanosensitivity
TLDR
Data indicate that nociceptin-induced mechanosensitivity changes in the rat knee depend upon NK1 receptor activation possibly through secondary release of substance P.
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
  • Z. JáraiJ. Wagner G. Kunos
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
It is suggested that Abn-cbd and cannabidiol are a selective agonist and antagonist, respectively, of an as-yet-unidentified endothelial receptor for anandamide, activation of which elicits NO-independent mesenteric vasodilation, possibly by means of the release of an endothelium-derived hyperpolarizing factor (EDHF).
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current
TLDR
GPR55 is established as a cannabinoid receptor with signaling distinct from CB1 and CB2, and its signaling pathway is found to involve Gq, G12, RhoA, actin, phospholipase C, and calcium release from IP3R-gated stores.
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
TLDR
The cloning and expression of a complementary DNA that encodes a G protein-coupled receptor that is involved in cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana are suggested.
Molecular characterization of a peripheral receptor for cannabinoids
TLDR
The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids.
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
TLDR
It is demonstrated that TRPV1 receptor could be a molecular target of the CBD antihyperalgesic action and not CB1 or CB2 or transient receptor potential vanilloid type 1.
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
  • L. HanušA. Breuer E. Fride
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity, demonstrating the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.
...
...